Replimune Group (NASDAQ:REPL) CFO Emily Luisa Hill Sells 9,256 Shares

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emily Luisa Hill also recently made the following trade(s):

• On Monday, August 10th, Emily Luisa Hill sold 11,448 shares of Replimune Group stock. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56.

Replimune Group Stock Down 4.9%

REPL stock traded down $0.77 during midday trading on Wednesday, reaching $14.81. 3,436,495 shares of the company were exchanged, compared to its average volume of 4,981,821. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.70. The stock’s 50-day simple moving average is $10.90 and its 200 day simple moving average is $7.90. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -4.70 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, equities analysts forecast that Replimune Group, Inc. will post -2.78 earnings per share for the current year.

Key Stories Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Replimune announced inducement equity awards for Chief Commercial Officer Michelle DiNapoli under Nasdaq Listing Rule 5635(c)(4). The grants are intended to support employee recruitment and retention, but will modestly increase potential share dilution. Replimune Announces Inducement Grants
• Neutral Sentiment: CFO Emily Luisa Hill sold 9,256 shares for approximately $132,176 at an average price of $14.28. The filing states the sale was made to cover tax-withholding obligations tied to vested equity awards; she continues to own 215,852 shares, reducing the signal of discretionary insider selling. SEC Insider Transaction Filing
• Negative Sentiment: Several law firms publicized the securities class action and reminded investors of the October 5, 2026 deadline to seek lead-plaintiff status. The complaints allege Replimune’s filings did not adequately disclose that FDA concerns about the RP1 study design remained unresolved. Although the allegations have not been proven, the legal uncertainty creates an overhang and could increase potential costs or liabilities. Replimune Securities Fraud Lawsuit Deadline Alert

Analyst Ratings Changes

Several equities analysts have issued reports on REPL shares. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a research report on Tuesday, June 30th. JPMorgan Chase & Co. boosted their target price on Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and upped their target price for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. Finally, Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group in the fourth quarter valued at about $29,000. Russell Investments Group Ltd. grew its holdings in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the last quarter. CWM LLC grew its holdings in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the last quarter. Essential Partners LLC increased its position in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets increased its position in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after acquiring an additional 6,873 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.